Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
COGT Cogent Biosciences
- 6.850
- -0.160-2.28%
Close Mar 10 16:00 ET
- 7.190
- +0.340+4.96%
Pre 05:19 ET
779.87MMarket Cap-3.53P/E (TTM)
7.030High6.600Low1.14MVolume6.860Open7.010Pre Close7.79MTurnover1.56%Turnover RatioLossP/E (Static)113.85MShares12.61052wk High5.35P/B502.18MFloat Cap5.73052wk Low--Dividend TTM73.31MShs Float174.200Historical High--Div YieldTTM6.13%Amplitude1.904Historical Low6.823Avg Price1Lot Size
Cogent Biosciences Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -35.26%-207.79M | -37.46%-60.58M | -36.90%-51.98M | -33.17%-42.7M | -32.93%-52.53M | -29.49%-153.62M | -49.86%-44.07M | -10.25%-37.97M | -21.21%-32.07M | -39.47%-39.52M |
| Net income from continuing operations | -32.98%-255.86M | -24.95%-67.93M | -27.54%-70.63M | -33.75%-58.95M | -51.21%-58.35M | -37.20%-192.41M | -37.22%-54.37M | -57.95%-55.38M | -26.19%-44.08M | -25.96%-38.59M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | --8K | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 21.27%4.35M | 39.55%1.11M | 28.30%1.1M | -11.18%1.08M | 47.44%1.07M | -38.96%3.59M | -15.26%794K | -76.96%855K | 81.49%1.22M | 29.11%723K |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | -25.00%-1.7M | --0 | --0 | --0 | ---1.7M |
| Change In working capital | 1.35%11.6M | -122.88%-1.13M | 94.41%13.4M | -41.03%2.58M | 31.85%-3.24M | 1,423.57%11.44M | -27.06%4.94M | 200.45%6.89M | 33.70%4.37M | -95.48%-4.76M |
| -Change in prepaid assets | -592.33%-4.33M | -282.93%-3.39M | 141.63%746K | -60.43%-592K | -248.73%-1.1M | 57.87%-626K | 13.35%1.85M | 18.91%-1.79M | -114.53%-369K | 57.12%-316K |
| -Change in payables and accrued expense | 33.36%17.31M | -23.48%2.61M | 45.18%13M | -27.51%3.51M | 57.18%-1.81M | 8.69%12.98M | -38.51%3.42M | 179.12%8.96M | 97.39%4.84M | -678.25%-4.23M |
| -Change in other current assets | 101.68%2K | 300.00%4K | --0 | --0 | 93.33%-2K | 88.31%-119K | -108.70%-2K | -168.50%-87K | --0 | 98.40%-30K |
| -Change in other current liabilities | -74.12%-1.39M | -13.13%-362K | -88.83%-355K | -235.64%-339K | -76.47%-330K | 90.84%-796K | 25.93%-320K | 97.65%-188K | -136.46%-101K | 66.00%-187K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -35.26%-207.79M | -37.46%-60.58M | -36.90%-51.98M | -33.17%-42.7M | -32.93%-52.53M | -29.49%-153.62M | -49.86%-44.07M | -10.25%-37.97M | -21.21%-32.07M | -39.47%-39.52M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 139.13%38.28M | 487.96%61.67M | 166.48%60.19M | -8.97%-84.63M | -98.26%1.04M | 21.56%-97.82M | -63.08%10.49M | 40.26%-90.54M | -6,688.55%-77.66M | 13,679.14%59.88M |
| Net PPE purchase and sale | 79.51%-573K | 76.19%-75K | -131.40%-280K | 88.23%-148K | 93.65%-70K | 59.26%-2.8M | 83.99%-315K | 96.35%-121K | -9.88%-1.26M | -150.11%-1.1M |
| Net investment purchase and sale | 140.88%38.85M | 471.51%61.75M | 166.88%60.47M | -10.57%-84.48M | -98.17%1.11M | 19.37%-95.03M | -64.43%10.8M | 39.00%-90.42M | ---76.4M | --60.99M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 139.13%38.28M | 487.96%61.67M | 166.48%60.19M | -8.97%-84.63M | -98.26%1.04M | 21.56%-97.82M | -63.08%10.49M | 40.26%-90.54M | -6,688.55%-77.66M | 13,679.14%59.88M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 31.13%214.45M | 26K | -37.60%624K | -100.16%-256K | 48,002.70%214.06M | -0.01%163.54M | 0 | 1.01%1M | -0.01%162.09M | 222.46%445K |
| Net common stock issuance | 31.84%213.34M | --0 | --0 | -100.23%-365K | --213.7M | -0.08%161.82M | --0 | 0.00%-170K | --161.99M | --0 |
| Proceeds from stock option exercised by employees | -35.06%1.12M | --26K | -46.67%624K | 6.86%109K | -20.00%356K | 6.45%1.72M | --0 | 0.86%1.17M | --102K | 222.46%445K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 31.13%214.45M | --26K | -37.60%624K | -100.16%-256K | 48,002.70%214.06M | -0.01%163.54M | --0 | 1.01%1M | -0.01%162.09M | 222.46%445K |
| Net cash flow | ||||||||||
| Beginning cash position | -62.29%53.23M | 11.79%97.05M | -58.84%88.22M | 33.25%215.8M | -62.29%53.23M | -36.12%141.14M | -38.79%86.81M | -34.42%214.32M | -15.78%161.95M | -36.12%141.14M |
| Current changes in cash | 151.11%44.94M | 103.34%1.12M | 106.92%8.83M | -343.64%-127.58M | 681.15%162.57M | -10.17%-87.91M | -4,823.90%-33.58M | 31.08%-127.51M | -61.07%52.36M | 172.68%20.81M |
| End cash Position | 84.42%98.17M | 84.42%98.17M | 11.79%97.05M | -58.84%88.22M | 33.25%215.8M | -62.29%53.23M | -62.29%53.23M | -38.79%86.81M | -34.42%214.32M | -15.78%161.95M |
| Free cash flow | -33.21%-208.36M | -36.65%-60.65M | -37.20%-52.26M | -28.59%-42.85M | -29.49%-52.6M | -24.64%-156.42M | -41.47%-44.39M | -0.90%-38.09M | -20.74%-33.32M | -41.16%-40.62M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |